SecBot SecBot
6-K ·Filed Jul 13, 2026

KMDA

KAMADA LTD
NEUTRAL
Impact 3/10
Horizonmonths Processed4mo ago SEC0001213900-26-077360
Notable filing: 6-K
Actionable Insight • Neutral

Monitor for the full publication of Dr. Calabrese's results later this year, as well as upcoming quarterly earnings (expected 2026 outlook range $200M-$205M revenue per prior 20-F) for any changes in CYTOGAM sales trajectory. No immediate trading catalyst from this clinical data highlight alone.

DirectionNeutral
Confidencehigh
Horizonmonths

CYTOGAM

● Neutral Named in this 6-K
Impact
Phase
Approved
Time to market
Already FDA-approved and commercially marketed
Next catalyst
None dated

What to watchCYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.17
T+0 close · Jul 13, 2026 · via day close
Latest settled
+13.11%
T+60 · $8.11
Vs SPY
+9.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 13 $7.17entry
  2. T+1 · 4mo ago +1.39%α +1.04% · $7.27
  3. T+5 · 4mo ago −1.67%α −0.89% · $7.05
  4. T+20 · 3mo ago −0.42%α −3.60% · $7.14
  5. T+60 · 6w ago +13.11%α +9.12% · $8.11
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kamada announced positive results from an investigator-initiated study of CYTOGAM presented at the 2026 ISHLT annual meeting. The data suggest CYTOGAM use in CMV high-risk lung transplant recipients is associated with improved clinical outcomes and potential immune modulation benefits. While supportive of the product's profile, this is a press release highlighting existing clinical data, not a catalyst with quantifiable revenue impact, and represents routine scientific communication.

Key Facts

  • Results from three posters on CYTOGAM (CMVIG) presented at the 2026 ISHLT annual meeting in Toronto
  • Retrospective analysis showed CMV high-risk lung transplant recipients not receiving CMVIG had worse clinical outcomes vs those who received it
  • Non-clinical in-vivo model suggested CMVIG blunted lung injury and improved mortality
  • CYTOGAM is the sole FDA-approved immunoglobulin product for CMV prophylaxis in kidney, lung, liver, pancreas and heart transplantation
  • CEO Amir London stated the data support increased product utilization for CYTOGAM
  • Full results to be published later this year

Financial Impact

No financial figures or revenue guidance provided in this filing. No material dollar amount cited.

CYTOGAM revenue (no figures provided)

Risk Factors

  • Study is investigator-initiated, not a Kamada-sponsored registrational trial, limited direct revenue impact
  • Forward-looking statements about increased CYTOGAM utilization remain aspirational without commercial execution proof
  • Geopolitical risks from Middle East conflicts and tariffs could affect broader operations as disclosed in the filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-077360
Document: ea0297771-6k_kamada.htm0001213900-26-077360
Document: 0001213900-26-077360-index-headers.html0001213900-26-077360
Document: 0001213900-26-077360-index.html0001213900-26-077360
Document: 0001213900-26-077360.txt0001213900-26-077360

Track record

25 reports on KMDA

Performance horizon

8 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 No price data
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
  4. Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  5. Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  6. Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  7. Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
  8. Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
  9. Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
  10. Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 9h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026